Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
NCT ID: NCT02244307
Last Updated: 2014-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4561 participants
OBSERVATIONAL
2000-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
NCT02245555
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224107
Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
NCT02244346
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia
NCT05236634
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with BPH treated with alpha-andrenergic blockade
alpha-adrenergic blocker
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
alpha-adrenergic blocker
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are already on class-1 alpha-blockers can only participate in the study if all information required is known and/or available
Exclusion Criteria
* Patients participating in another study
* History of BPH surgery
* Prostate cancer
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
527.28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.